CD19 and systemic lupus erythematosus: CD19 CAR T cell therapy as precision medicine approach in conjunction with deep molecular phenotyping, thus, provides support for the central role of autoreactive B cells during the pathogenesis of SLE as well as for the B cell–dependent increase in type I IFN signaling previously observed in PBMCs of patients with SLE.